Patients with diabetic retinopathy have a high risk of developing macular edema after cataract surgery. Intravitreal injections of aflibercept might result in fewer patients developing macular edema in this patient population.
Lynda Charters
Advertisement
Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
Articles by Lynda Charters
Activation of Tie2–as a result of subcutaneous administration of AKB-9778 (Aerpio Therapeutics) in combination with an anti-vascular endothelial growth factor (anti-VEGF) therapy–enhances the effect of an anti-VEGF drug on diabetic macular edema (DME).
A new class of ophthalmic drug continues to show promise for treating patients with diabetic macular edema (DME).
Advertisement
Advertisement
Advertisement
Trending on Modern Retina
1
The Retina TL;DR: Advancing sustained VEGF suppression with EYP-1901 with Jay S. Duker, MD
2
Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA
3
Q&A: The ARCHER trial and the importance of continued GA research
4
Challenges Reported by Young Physicians in Managing Geographic Atrophy and How these Shape Patient Care
5
